HCW 2026: As it approaches a BLA filing for its viral immunotherapy in prostate cancer, Candel has published its pivotal phase 3 data in Lancet Oncology and presented extended data at AUA

HCW 2026: As it approaches a BLA filing for its viral immunotherapy in prostate cancer, Candel has published its pivotal phase 3 data in Lancet Oncology and presented extended data at AUA16 sept11 min

Escuchar en SpotifyTambién funciona en tu navegador

Apple PodcastsAbrir
Pocket Castsabre el pódcast
Amazon Musicabre el pódcast
Deezerabre el pódcast
Overcastabre el pódcast

11 apps más

Player FMabre el pódcast
Castroabre el pódcast
Podcast Addictabre el pódcast
YouTubeAbrir
Castboxabre el pódcast
Podcast Republicabre el pódcast
AntennaPodabre el pódcast
iHeartRadioabre el pódcast
TuneInabre el pódcast
Fountainabre el pódcast

<p>CEO Paul Peter Tak walks us through how the data has settled, and the steps the company needs to take before officially filing the BLA in Q4. Plus, an update on lung cancer.</p>